Figure 3.

CD4⁺ T-cell and CD8⁺ T-cell numbers, and CD4⁺/CD8⁺ T-cell ratio during follow-up stratified by Tat vaccine regimens. Baseline values (left panels) and annual changes (right panels) from ISS T-002 trial baseline of CD4⁺ T-cells (A), CD8⁺ T-cells (B), and CD4⁺/CD8⁺ T-cell ratio (C) over 8 years of follow-up are shown according to the Tat vaccine regimen. The number of participants tested are as follows: Tat 7.5 μg, 3 ×: year 1 n = 21, year 2 n = 14, year 3 n = 9, year 4 n = 10, year 5 n = 13, year 6 n = 18, year 7 n = 12 year 8+ n = 7; Tat 7.5 μg, 5 ×: year 1 n = 20, year 2 n = 14, year 3 n = 7, year 4 n = 10, year 5 n = 13, year 6 n = 19, year 7 n = 12 year 8+ n = 7; Tat 30 μg, 3 ×: year 1 n = 27, year 2 n = 17, year 3 n = 14, year 4 n = 10, year 5 n = 15, year 6 n = 25, year 7 n = 19 year 8+ n = 11; Tat 30 μg, 5 ×: year 1 n = 24, year 2 n = 18, year 3 n = 134, year 4 n = 7, year 5 n = 13, year 6 n = 20, year 7 n = 15 year 8+ n = 12. Data are presented as mean values with standard error. A longitudinal analysis for repeated measurements was applied. p-values assess the values at year 1–8 after immunization vs. baseline values.